Therapy News and Research

RSS

FlowCardia commences enrollment in CROSSER CTO Recanalization Catheter study

FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced Dr. John Paul Runyon from The Christ Hospital in Cincinnati, Ohio successfully enrolled the first patient into the CENTRAL (Crosser ENters The Right Arterial Lumen) study.

9 Feb 2010

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.

9 Feb 2010

Gene linked to PMDD and other maladies during menstrual cycle

Scientists have identified a gene they say is a strong candidate for involvement in premenstrual dysphoric disorder (PMDD) and other maladies associated with the natural flux in hormones during the menstrual cycle. In a paper to be published today in the Proceedings of the National Academy of Sciences, Rockefeller University researchers detail experiments in mice showing that a common human variant of the gene increases anxiety, dampens curiosity and tweaks the effects of estrogen on the brain, impairing memory.

9 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

Picis introduces LYNX C/Point revenue management solution for chemotherapy clinics

Picis today announced the immediate availability of an enhancement to its Picis LYNX C/Point® revenue management solution designed specifically for hospital-owned chemotherapy clinics.

9 Feb 2010

Study highlights the importance of effective therapy to fight depression

People with depression generate higher absentee and disability costs on the job -- even when they are treated with antidepressants, according to a study published today in the Journal of Occupational and Environmental Medicine.

9 Feb 2010

Study validates Transgenomic's COLD-PCR technology for colorectal tumor-associated KRAS mutation detection

Transgenomic, Inc. announced today that it has completed a preliminary study with a leading pharmaceutical company that validates the use of its licensed COLD-PCR technology to detect colorectal tumor-associated KRAS mutations that determine efficacy of recently developed therapies. These were detected in plasma samples in which the mutation levels were too low for detection by standard DNA analysis methodologies such as Sanger sequencing.

9 Feb 2010

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.

9 Feb 2010

Racial disparities continue in U.S. cancer screening practices

The incidence of advanced breast cancer diagnosis among black women remained 30 percent to 90 percent higher compared to white women between 1992 and 2004, according to new findings by researchers at Fred Hutchinson Cancer Research Center. In addition, the disparity in the incidence of advance colorectal cancer actually widened over this time period as rates fell among whites but increased slightly among blacks.

9 Feb 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.

9 Feb 2010

Advanced paternal age increases autism risk only when the mother is younger

Advanced maternal age is linked to a significantly elevated risk of having a child with autism, regardless of the father's age, according to an exhaustive study of all births in California during the 1990s by UC Davis Health System researchers. Advanced paternal age is associated with elevated autism risk only when the father is older and the mother is under 30, the study found.

9 Feb 2010

Exposure to electronic media is not linked to headaches

Use of most electronic media is not associated with headaches, at least not in adolescents. A study of 1025 13-17 year olds, published in the open access journal BMC Neurology, found no association between the use of computer games, mobile phones or television and the occurrence of headaches or migraines.

9 Feb 2010

New nursing education modules now available from March of Dimes

For nurses seeking up-to-date and cost-effective continuing education on the care of mothers and babies, the March of Dimes is now offering three new publications (modules).

9 Feb 2010

Boston researchers identify new mechanism that inhibit tumor growth in mice

A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.

9 Feb 2010

Skilled Healthcare Group announces fourth-quarter and full-year 2009 results

Skilled Healthcare Group, Inc. today reported consolidated revenues for the year ended December 31, 2009 of $759.8 million, an increase of 3.6 percent compared to 2008. Consolidated revenues were $189.0 million for the three-month period ended December 31, 2009, compared to $189.8 million for the three-month period ended December 31, 2008.

9 Feb 2010

Study indicates women receiving antiretroviral therapy are more likely to become pregnant

In PLoS Medicine this week a study conducted in a multi-country HIV treatment program in sub-Saharan Africa has found that pregnancy rates increase in HIV-infected women after they start antiretroviral therapy (ART).

9 Feb 2010

BD recalls certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems

BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.

From BD (Becton, Dickinson and Company) 9 Feb 2010

Emerging Healthcare Solutions issues Term Sheet review to ThromboVision

Emerging Healthcare Solutions, Inc. announced today that management has formally delivered an actionable Term Sheet to ThromboVision for review and that follow up communications have been very favorable.

9 Feb 2010

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared to the royalty rate set under the original licensing agreement signed in 2004 for sales in the rest of the world.

9 Feb 2010

Therapy News and Research

FlowCardia commences enrollment in CROSSER CTO Recanalization Catheter study

Biogen Idec reports 2009 fourth quarter and full year earnings

Gene linked to PMDD and other maladies during menstrual cycle

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

Picis introduces LYNX C/Point revenue management solution for chemotherapy clinics

Study highlights the importance of effective therapy to fight depression

Study validates Transgenomic's COLD-PCR technology for colorectal tumor-associated KRAS mutation detection

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Racial disparities continue in U.S. cancer screening practices

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

Advanced paternal age increases autism risk only when the mother is younger

Exposure to electronic media is not linked to headaches

New nursing education modules now available from March of Dimes

Boston researchers identify new mechanism that inhibit tumor growth in mice

Skilled Healthcare Group announces fourth-quarter and full-year 2009 results

Study indicates women receiving antiretroviral therapy are more likely to become pregnant

BD recalls certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems

Emerging Healthcare Solutions issues Term Sheet review to ThromboVision

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News